| Sensei Biotherapeutics Reports First Quarter 2025 Financial Results and Updates on Clinical Progress |
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. “This was a breakthrough quarter for Sensei,” said John Celebi, President and CEO. |
globenewswire.com |
2025-05-06 11:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Participate in the Canaccord Genuity Horizons in Oncology Virtual Conference |
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. |
globenewswire.com |
2025-04-02 11:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Reports Full Year 2024 Financial Results and Update on Clinical Progress |
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant “hot” tumor patient population - |
globenewswire.com |
2025-03-28 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Reports Favorable Preliminary Dose Expansion Data for Solnerstotug in PD-(L)1 Resistant Tumors |
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – |
globenewswire.com |
2025-03-27 18:05:00 |
Czytaj oryginał (ang.) |
| What Makes Sensei Biotherapeutics (SNSE) a New Buy Stock |
Sensei Biotherapeutics (SNSE) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). |
zacks.com |
2025-02-06 15:06:13 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Participate in Oppenheimer's 35th Annual Healthcare Life Sciences Conference |
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET. |
globenewswire.com |
2025-02-04 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones |
- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its lead program, solnerstotug (SNS-101) and upcoming milestones. “2024 was a noteworthy year for Sensei and our pioneering lead program, solnerstotug. |
globenewswire.com |
2025-01-08 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Participate in Citi's 2024 Global Healthcare Conference |
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi's 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL. |
globenewswire.com |
2024-11-27 18:05:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights |
- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. “The third quarter of 2024 saw significant progress in advancing patient enrollment in the dose expansion portion of the Phase 1 study for SNS-101 across dose levels and patients with primary and acquired resistance to PD-1 inhibitors. |
globenewswire.com |
2024-11-14 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Present at Two Upcoming Scientific Conferences |
BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences. |
globenewswire.com |
2024-10-29 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Present Preclinical Data on SNS-103 at the CRI-ENCI Eighth International Immunotherapy Conference |
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD. |
globenewswire.com |
2024-09-04 20:05:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Present at Upcoming Conferences |
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024: |
globenewswire.com |
2024-09-04 11:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights |
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. “Collectively, the clinical data presented on SNS-101 over the past six months demonstrated early signs of clinical activity in a patient population generally resistant to immunotherapy, a well-tolerated safety profile, and the avoidance of a pharmacokinetic sink that hindered first-generation approaches to targeting VISTA,” said John Celebi, President and Chief Executive Officer. |
globenewswire.com |
2024-08-06 11:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Participate in Jefferies Global Healthcare Conference |
BOSTON, May 30, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at the Jefferies Global Healthcare Conference, being held in New York, NY, on Thursday, June 6, 2024 at 8:30 a.m. ET. |
globenewswire.com |
2024-05-30 11:30:00 |
Czytaj oryginał (ang.) |
| Why Is Sensei Biotherapeutics (SNSE) Stock Down 40% Today? |
Sensei Biotherapeutics (NASDAQ: SNSE ) stock is falling on Friday after it failed to impress investors with its latest Phase 1/2 clinical trial data for SNS-101. SNS-101 is a human monoclonal antibody targeting the immune checkpoint VISTA. |
investorplace.com |
2024-05-24 12:27:24 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Presents Promising Clinical Data from Phase 1 Dose Escalation Study of SNS-101 |
- Once every 3-week dosing of SNS-101 demonstrates initial signs of promising clinical activity - - Pharmacokinetic and safety profile validate conditionally active approach - - Investor webcast to be held on Monday, June 3 at 8:00 a.m. ET - BOSTON, May 23, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported encouraging clinical data from the dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation). |
globenewswire.com |
2024-05-23 21:10:00 |
Czytaj oryginał (ang.) |
| EGLE Therapeutics Strengthens its Leadership Team with the Appointment of Pejvack Motlagh, MD, MSc, as Chief Medical Officer and its Board of Directors with Appointment of John Celebi, MBA, as Independent Board Member |
PARIS--(BUSINESS WIRE)--EGLE Therapeutics, a clinical-stage biotechnology company uniquely positioned to advance the next generation of regulatory T cell-focused therapies for oncology and auto-immunity, announced today the appointment of Pejvack Motlagh MD, MSc, as Chief Medical Officer and John Celebi, as Independent Board Member. “We are excited to welcome Pejvack and John at Egle and to benefit from their strong experience. The appointment of Dr Motlagh is critical for Egle, as the company. |
businesswire.com |
2024-05-10 15:45:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights |
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provided corporate updates. “Building upon our initial data for SNS-101, which we believe support a favorable and potentially best-in-class clinical safety and PK profile, we now look forward to sharing topline dose escalation data at ASCO in June and initial dose expansion data in the fourth quarter of this year,” said John Celebi, President and Chief Executive Officer. |
globenewswire.com |
2024-05-09 11:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Present Topline Clinical Data from the SNS-101 Phase I Dose Escalation Study at the 2024 ASCO Annual Meeting |
BOSTON, April 24, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that topline clinical data from the monotherapy and combination dose escalation portion of its Phase 1/2 trial of SNS-101, a conditionally active, human monoclonal antibody targeting the immune checkpoint VISTA (V-domain Ig suppressor of T cell activation), will be presented in a poster presentation at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31 – June 4, 2024. |
globenewswire.com |
2024-04-24 20:05:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Participate in Canaccord Genuity's Horizons in Oncology Virtual Conference |
BOSTON, April 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), an immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate in a panel titled ‘KRAS and VISTA - Better Approaches for Key Targets' at Canaccord Genuity's Horizons in Oncology Virtual Conference on Monday, April 15th at 2:00 p.m. ET. |
globenewswire.com |
2024-04-09 11:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Announces Nature Communications Publication Describing Mechanism of Action of SNS-101 Selectively Targeting the Active Form of VISTA within the Tumor Microenvironment |
BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the publication of a peer-reviewed research paper in Nature Communications. The research was conducted by scientists at Sensei Biotherapeutics in collaboration with genOway and the laboratory of Dr. Robert Schreiber at the Washington University, St. Louis School of Medicine. |
globenewswire.com |
2024-04-04 20:05:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Participate in the 3rd Annual VISTA Symposium |
BOSTON, March 22, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will participate on a panel titled ‘Anti-VISTA Immunotherapies in Clinical Development' at the 3rd Annual VISTA Symposium. The VISTA Symposium will convene scientific experts and industry leaders to explore the important emerging role of VISTA in cancer immunotherapy and will review the latest insights on VISTA biology, the growing potential of VISTA as a therapeutic target in multiple cancer indications and share updates on the ongoing clinical development of anti-VISTA therapies. The symposium will take place virtually on Wednesday, March 27 from 11 a.m. to 3:30 p.m. ET. |
globenewswire.com |
2024-03-22 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Present New Preclinical Data at Upcoming Scientific Conferences |
BOSTON, March 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that the company will present preclinical data on its conditionally active immuno-oncology programs at upcoming scientific conferences. |
globenewswire.com |
2024-03-06 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Reports Full Year 2023 Financial Results and Recent Business Highlights |
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - |
globenewswire.com |
2024-02-28 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics to Present at Upcoming Conferences |
BOSTON, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in February 2024: |
globenewswire.com |
2024-02-07 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Provides Corporate Update and Highlights Key Upcoming Milestones |
- Completed SNS-101 monotherapy dose escalation through 15 mg/kg with no dose limiting toxicities - - Expands patient cohort in specific tumor types - - Multiple clinical milestones expected in 2024 - - Strong balance sheet with cash runway extended into the fourth quarter of 2025 - BOSTON, Jan. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its research and development programs and upcoming milestones. “In 2023, we significantly advanced our lead clinical asset while prudently maintaining our strong balance sheet,” said John Celebi, President and Chief Executive Officer. |
globenewswire.com |
2024-01-04 09:30:00 |
Czytaj oryginał (ang.) |
| Sensei Biotherapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights |
- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported - |
globenewswire.com |
2023-11-07 09:30:00 |
Czytaj oryginał (ang.) |